Salubris wins NMPA approval for hyperlipidemia drug trials

Shenzhen Salubris Pharmaceuticals announced it has received approval from the National Medical Products Administration for clinical trials of its self-developed innovative small molecule drug, SAL0139. The drug is intended for the treatment of hyperlipidemia, marking a crucial milestone for the company's research and development efforts in addressing metabolic diseases.

Hyperlipidemia is a prevalent metabolic disorder with a high risk of systemic complications if left uncontrolled, largely due to the accumulation of LDL-C. Preclinical studies indicate that SAL0139 possesses the potential to reduce LDL-C levels, offering a promising new treatment option that could enhance patient compliance and satisfy unmet clinical needs. The successful development and eventual market approval of SAL0139 would also significantly enrich Salubris's pipeline in chronic disease management.

Salubris will proceed with the clinical trials in accordance with national drug registration regulations. The company acknowledges the inherent risks and extended timelines associated with drug development, emphasizing that this development is not expected to materially impact its short-term financial performance. Investors are advised to exercise caution and rationalize investment decisions, as the company commits to timely disclosure of future progress.